ECCN European Conference on Clinical Neuroimaging - Brussels Belgium 2018

Save the date : Brussels, Belgium March, 26-27, 2018



Save the date : Brussels, Belgium March, 26-27, 2018

Experimental psychologist/psychobiologist, PhD in Neuroscience. She performs research in structural imaging, using advanced algorithms to investigate correlates of neurodegenerative disorders, psychiatric conditions, or other normal features (personality; genetics). Currently involved in the validation of diagnostic biomarkers for Alzheimer’s disease, including methodological aspects, and the definition of standard operating procedures.

Save the date : Brussels, Belgium March, 26-27, 2018

MATTHEW BROOKES (United Kingdom)
Matt Brookes is a physicist working on the development and application of multi-modal neuroimaging – particularly magnetoencephalography (MEG). He has made significant contributions to the technical development of MEG, multi-modal imaging, and the use of MEG for the measurement of functional connectivity between cortical regions. In his most recent work, he has been involved in the development of next generation ‘quantum’ sensors for use in detection of neuromagnetic fields.


Save the date : Brussels, Belgium March, 26-27, 2018

WILLEM DE HAAN (The Netherlands)
In 2012, I defended my PhD thesis about functional brain network analysis in Alzheimer’s Disease. The main goal of my research is to better understand the relation between brain activity and dementia. In the past years, I have focused on computational network modeling of AD. This approach may help to understand both the cause and course of the disease, and guide treatment selection by solving how to modulate abnormal brain activity in order to optimize network function. In 2018, I will combine my research efforts with work as a cognitive neurologist for the VUmc Alzheimer Center.

Save the date : Brussels, Belgium March, 26-27, 2018

Being board certified in clinical neurology and neurological revalidation, Sebastiaan is specialized in neurodegenerative brain disorders that cause dementia. Sebastiaan coordinates the memory clinic of Hospital Network Antwerp (ZNA) and is full Professor of Neurosciences and Neurochemistry at the University of Antwerp, where he established the Reference Center for Biological Markers of Dementia (BIODEM) in 2004. He (co-)authored 267 PubMed cited papers, resulting in a WoS h-index of 51. Sebastiaan is secretary-general of the Belgian Neurological Society, vice-president of the Belgian Dementia Council and executive steering committee member of the European Alzheimer’s Disease Consortium (EADC).


Save the date : Brussels, Belgium March, 26-27, 2018
Dr. Valentina Garibotto is senior physician and senior lecturer at the Geneva University and Geneva University Hospital. Her research group works on molecular imaging of neurodegenerative diseases, with a specific interest in causative and protecting factors and on novel therapeutic approaches ( ). Molecular imaging represents a unique window to the processes ongoing in the healthy and diseased brain and has already dramatically advanced our knowledge and understanding of neurodegeneration: the next challenge is cure. These research projects are mainly supported by the Swiss National Research foundation, the Velux Stiftung and the Aetas foundation.

Dr. Garibotto obtained her doctorate in medicine from the Genoa University Hospital in 2003, her specialization in nuclear medicine at the San Raffaele Hospital and Bicocca University in Milan in 2007 and the title of Privat Docent from the Geneva University in 2014. She has authored 98 peer reviewed articles (H index: 20) in the fields of clinical neuroimaging and nuclear medicine. She is Secretary of the Neuroimaging Committee of the European Association of Nuclear Medicine and actively involved in a number of European initiatives fostering molecular imaging of cognitive disturbances, such as the European Alzheimer Disease Consortium PET, the European-Dementia with Lewy Body study group and the AMYPAD initiative. She’s teaching molecular imaging at the pregraduate and postgraduate level in national and international courses, namely within the European School of Multimodality Imaging and Therapy (ESMIT).

Save the date : Brussels, Belgium March, 26-27, 2018
Formal education in biology and physics at the University of Cologne, Germany, and the University of Seville, Spain. Since 2012 research associate in the Clinical Dementia Research section of the DZNE-Rostock, headed by Prof. Dr. Stefan Teipel. Received PhD in experimental psychiatry (summa cum laude) from the University of Rostock (2014). Research focus on multimodal imaging techniques for studying neurodegenerative disease pathology in-vivo (> 60 published research articles on this topic in peer-reviewed journals).



Save the date : Brussels, Belgium March, 26-27, 2018
Andriaan LAMMERTSMA (The Netherlands)

Prof. Adriaan A. Lammertsma, PhD, has been active in PET research since 1979, when he joined the MRC Cyclotron Unit, Hammersmith Hospital in London. Apart from a sabbatical year at UCLA, Los Angeles, he stayed in London until 1996, when he moved to the VU University Medical Center in Amsterdam. Over the years his research focus has been the development and application of tracer kinetic models for quantitative PET studies with applications in neurology, cardiology and oncology. In addition, he was one of the first to recognise the value of PET in both drug development and precision medicine. He is the 2012 recipient of the Kuhl-Lassen Award from the Society of Nuclear Medicine and the 2015 recipient of the ESMI Award from the European Society of Molecular Imaging. Adriaan Lammertsma is co-author of nearly 500 peer reviewed paper.

Save the date : Brussels, Belgium March, 26-27, 2018
Dante Mantini is Associate Professor at the Research Center for Motor Control and Neuroplasticity of the KU Leuven since 2015. He moved to the field of neuroscience after a Master degree in electrical engineering (2002) and a PhD in computer science (2006) at the Marche Polytechnic University (Italy). He was among the first scientists who used neuroimaging, in particular fMRI and MEG/EEG, to investigate dynamic interactions between distant brain regions. The main goal of his current research is to better understand the relationships between connectivity in the human brain and behaviour.


Save the date : Brussels, Belgium March, 26-27, 2018
Daniela Perani, MD, Neurologist and Radiologist, Full Professor of Neuroscience, University Vita-Salute San Raffaele, Milano, Italy. Coordinator of several National and International Research Projects in Neurology and Neuroscience. Her researches deal with in vivo molecular neuroimaging studies of neurological disease, in particular neurodegenerative dementias, and with cognitive neuroscience, addressing the neural correlates of language, memory, music perception and cognitive brain reserve by neuroimaging.
She is author of more than 250 full papers, HI 86, citation number: 30632

Save the date : Brussels, Belgium March, 26-27, 2018
Professor, Faculty of Medecine, University of Liège, Department of Clinical Sciences, Neuroimaging of Memory and Cognitive Readaptation.
Specialist in Neuropsychiatry, PhD in Biomedical and Experimental Sciences, Specialist in Nuclear Medicine, “Agrégé de l'Enseignement Supérieur ».
Neurologist, responsible for the Memory Clinic, Department of Neurology, CHU Liège ( ),
Medical director GIGA-Cyclotron Research Centre in vivo imaging, University of Liège (
Researches on physiology and physiopathology of cognitive functions and behaviour in normal and pathological aging, related to neuroimaging of neural networks and their integration.
Publications :

Save the date : Brussels, Belgium March, 26-27, 2018
Schmidt is a Senior Director in Experimental Medicine for Janssen Pharmaceutica in Beerse, Belgium.  He received his medical degree from the University of Chicago in 1983 and entered postgraduate training in psychiatry in the US Navy.  Dr. Schmidt was a research fellow in the National Institute of Mental Health (NIMH) where he focused on the use of functional imaging as a pharmacodynamic marker.  Following fellowship, he worked at Lilly, Novartis, and now Janssen. He is responsible for clinical testing of NMEs for psychiatric indications through proof of concept, and has led a preclinical imaging group for development of site specific PET tracers and then qualifying them in human.  He has authored over 75 peer-reviewed manuscripts, reviews, and book chapters, many on the use of imaging for CNS drug development.

Save the date : Brussels, Belgium March, 26-27, 2018

Thilo van Eimeren is the director of multimodal brain imaging ( at the Department of Nuclear Medicine at the University Hospital of Cologne and associate professor at the University of Cologne. Furthermore, he is assistant medical director of the Department of Neurology at the University Hospital of Cologne and affiliated researcher at the Helmholtz Research Centers in Jülich and the German Center for Neurodegenerative Diseases (DZNE). He received his MD degree from the Ludwig-Maximilian University (LMU) and Technical University (TU) of Munich, Germany and is a board certified neurologist since 2011. His research focuses on multimodal functional and molecular imaging in neuroscience with regard to better understanding of brain physiology and pathophysiology, e.g. to improve early diagnosis and therapy monitoring in neurodegenerative disorders and the identification of compensatory mechanisms.

Save the date : Brussels, Belgium March, 26-27, 2018

Koen Van Laere is head of nuclear medicine and the PET-MR unit at KU Leuven University/University Hospital where he started his career 15 years ago, after graduating from Gent University with a medical PhD (2001) and MD specialisation in nuclear medicine (2002) and a PhD in radiation physics (1992). His main research interests are PET radioligand development and their applications in neurodegeneration (in particular movement disorders, ALS and dementia), psychiatric disorders and drug development. He is (co)author of over 330 peer reviewed scientific manuscripts and book chapters (HI 54). The nuclear medicine department in Leuven has a full GMP radiopharmaceutical production facility, 2 PET-CT (including GE MI4) and a GE Signa PET-MR, as well as a full preclinical facility including an integrated microPET-MR (7T, Bruker). There is an established base for preclinical and clinical academic and industry-sponsored PET tracer studies and data processing, with expertise in over 15 first-in-man tracer studies in collaboration with an on-site GMP certified Phase I unit. 

Save the date : Brussels, Belgium March, 26-27, 2018

Andrea Varrone, MD, PhD, Associate Professor of Nuclear Medicine at the Department of clinical neuroscience, Karolinska Institutet, Stockholm, Sweden. He is head of the PET Unit and research group leader. The focus of his research is the development of PET imaging markers for the study of neurodegenerative disorders, in particular Parkinson´s and Huntington´s disease. He is author of more than 120 papers, including reviews and procedural guidelines; HI 29, 2427 citations. 


               Share Share

News | general information | Archives | Press Presse | Newsletters | DOCUMENTS